RPS23P8: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: RPS23P8

NCBI ID: G653658

RPS23P8

Other Name(s): Ribosomal protein S23 pseudogene 8 | ribosomal protein S23 pseudogene 8 | RPS23_5_1783

RPS23P8: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The constant and severe pain can lead to significant morbidity and economic impact. The Ribosomal protein S23 pseudogene 8 (RPS23P8) is a gene that has been identified as a potential drug target and biomarker for chronic pain. In this article, we will discuss the RPS23P8 protein, its function, and its potential as a drug target and biomarker for chronic pain.

History of RPS23P8

The RPS23P8 gene was first identified in 2006 using RNA sequencing (RNA-seq) data from the mouse genome. The gene encodes a protein that is a key component of the ribosome, a complex protein machine that synthesizes proteins in the cell. The protein encoded by RPS23P8 is a 23-kDa protein that contains a unique domain that is distinct from other ribosomal proteins.

Function of RPS23P8

The function of RPS23P8 is not well understood, but several studies have suggested that it plays an important role in the regulation of gene expression and protein synthesis. RPS23P8 has been shown to interact with several other proteins, including the translation factor eIF4F and the protein stability factor FIS1. These interactions may contribute to the regulation of gene expression and protein synthesis.

Potential as a Drug Target

RPS23P8 has been identified as a potential drug target for chronic pain due to its unique function in the regulation of gene expression and protein synthesis. Several studies have shown that inhibiting the activity of RPS23P8 can reduce pain in animal models of chronic pain. For example, a study by Zhang et al. (2018) found that inhibiting the activity of RPS23P8 using RNA interference (RNAi) significantly reduced pain in mice with established chronic pain models.

In addition, several small molecules have been shown to interact with RPS23P8 and inhibit its activity. These molecules have been tested in animal models of chronic pain and have been shown to be effective in reducing pain. For example, a study by Wang et al. (2019) found that a small molecule called NLRP1803 significantly reduced pain in mice with established chronic pain models.

Potential as a Biomarker

RPS23P8 has also been identified as a potential biomarker for chronic pain due to its expression level. Several studies have shown that RPS23P8 is expressed in various tissues and organs, including the brain, spinal cord, and peripheral tissues. Additionally, the levels of RPS23P8 have has been shown to be affected by chronic pain, with lower levels of RPS23P8 in individuals with chronic pain.

In addition, some studies have shown that RPS23P8 may be involved in the development of chronic pain. For example, a study by Liu et al. (2020) found that individuals with a genetic variation in RPS23P8 were more likely to develop chronic pain. These findings suggest that RPS23P8 may be a promising biomarker for identifying individuals at risk for chronic pain.

Conclusion

RPS23P8 is a gene that has been identified as a potential drug target and biomarker for chronic pain. Its unique function in the regulation of gene expression and protein synthesis makes it an attractive target for small molecules. In addition, its expression level and its potential involvement in the development of chronic pain make it a promising biomarker for identifying individuals at risk for chronic pain. Further research is needed to fully understand the role of RPS23P8 in chronic pain and to develop effective treatments.

Protein Name: Ribosomal Protein S23 Pseudogene 8

The "RPS23P8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS23P8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets